Lung cancer (Amsterdam, Netherlands) · 2009
Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Igawa Satoshi, Murakami Haruyasu, Takahashi Toshiaki, Nakamura Yukiko, Tsuya Asuka, Naito Tateaki, Kaira Kyoichi, Ono Akira, Shukuya Takehito, Tamiya Akihiro, Endo Masahiro, Yamamoto Nobuyuki
Аннотация
BACKGROUND: Thymic carcinoma is a very rarely encountered neoplasm and no optimal chemotherapeutic regimen has been established yet.
METHODS: The records of previously untreated thymic carcinoma patients with unresectable disease who had been treated with paclitaxel and carboplatin as first-line chemotherapy between 2003 and 2008 were reviewed, retrospectively. Paclitaxel was administered at the dose of 200mg/m(2) and carboplatin at an AUC of 6 on day 1, with the treatment cycle repeated every 3 weeks.
RESULTS: Eleven patients were registered, and a total of 45 cycles of carboplatin/paclitaxel were administered (median cycles per patient, 4; range, 2-6). Although the principal toxicity of this regimen was neutropenia, with grade 3 or more severe neutropenia being observed in nine patients (82%), there were no cases of febrile neutropenia. There were also no cases of grade 3 or more severe peripheral sensory neuropathy. Thus, the toxicity profile of the treatment regimen was acceptable. The overall response rate was 36%, and the median survival time and median progression-free survival were 22.7 months and 7.9 months, respectively.
CONCLUSION: Combined paclitaxel+carboplatin therapy exhibits activity and acceptable toxicity in the first-line setting in patients with unresectable thymic carcinoma.
METHODS: The records of previously untreated thymic carcinoma patients with unresectable disease who had been treated with paclitaxel and carboplatin as first-line chemotherapy between 2003 and 2008 were reviewed, retrospectively. Paclitaxel was administered at the dose of 200mg/m(2) and carboplatin at an AUC of 6 on day 1, with the treatment cycle repeated every 3 weeks.
RESULTS: Eleven patients were registered, and a total of 45 cycles of carboplatin/paclitaxel were administered (median cycles per patient, 4; range, 2-6). Although the principal toxicity of this regimen was neutropenia, with grade 3 or more severe neutropenia being observed in nine patients (82%), there were no cases of febrile neutropenia. There were also no cases of grade 3 or more severe peripheral sensory neuropathy. Thus, the toxicity profile of the treatment regimen was acceptable. The overall response rate was 36%, and the median survival time and median progression-free survival were 22.7 months and 7.9 months, respectively.
CONCLUSION: Combined paclitaxel+carboplatin therapy exhibits activity and acceptable toxicity in the first-line setting in patients with unresectable thymic carcinoma.